B8FK.XETRA Biofrontera AG
- Market cap
- EUR 18.2M
- P/E
- -
- P/B
- 0.91x
- ROE
- 54.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is B8FK.XETRA undervalued?
Graham numberThe Graham number of Biofrontera AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biofrontera AG fundamental analysis
No fundamental analysis for Biofrontera AG yet.
Biofrontera AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the tr…
Full company profileBiofrontera AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biofrontera AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.13M | 12.0M | 21.1M | 31.3M | 30.3M | 28.8M | 25.7M | 32.2M | 12.2M | 13.2M | 18.1M |
| Gross Profit | 4.48M | 10.3M | 16.7M | 26.4M | 26.8M | 24.9M | 21.0M | 25.4M | 10.1M | 10.9M | 14.6M |
| Operating Income | -11.8M | -13.9M | -18.5M | -23.4M | -5.61M | -35.3M | 1.59M | 4.78M | -1.59M | -1.03M | 2.88M |
| EBITDA | -10.1M | -14.1M | -16.7M | -20.2M | -277K | -12.6M | 2.34M | 5.57M | -301K | -560K | 2.88M |
| Net Income | -10.6M | -16.1M | -8.88M | -7.36M | -13.0M | 37.7M | -44.2M | -369K | -4.35M | -3.97M | 11.1M |
| EPS | -0.33 | -0.39 | -0.19 | -0.15 | -0.22 | 0.64 | -0.77 | -0.01 | -0.72 | -0.65 | 1.81 |
| Balance Sheet | |||||||||||
| Total Assets | 23.9M | 19.8M | 39.1M | 58.4M | 56.4M | 76.1M | 32.7M | 30.7M | 30.2M | 20.6M | 26.0M |
| Total Liabilities | 8.04M | 16.5M | 22.8M | 48.4M | 49.0M | 18.7M | 12.4M | 10.8M | 11.3M | 5.80M | 5.59M |
| Shareholders' Equity | 15.8M | 3.38M | 16.4M | 9.96M | 7.38M | 57.4M | 20.3M | 20.0M | 18.9M | 14.9M | 20.4M |
| Cash & Short-term Investments | 16.5M | 11.7M | 19.5M | 12.2M | 16.6M | 6.91M | 6.38M | 3.08M | 3.28M | 3.62M | 7.26M |
| Total Debt | 3.88M | 12.5M | 13.6M | 23.3M | 23.9M | 3.30M | 1.50M | 1.15M | 765K | 626K | 1.10M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -10.7M | -13.1M | -13.4M | -32.9M | -2.85M | 30.4M | -3.90M | -1.92M | -2.54M | -4.40M | - |
| Capital Expenditure | 485K | 397K | 513K | 1.85M | 774K | 629K | 981K | 912K | 210K | 51.0K | 0.00 |
| Free Cash Flow | -11.2M | -13.5M | -13.9M | -34.7M | -3.62M | 29.8M | -4.88M | -2.83M | -2.75M | -4.45M | - |
| Ratios | |||||||||||
| ROE | -66.8% | -476.2% | -54.3% | -73.9% | -176.6% | 65.7% | -217.2% | -1.8% | -23.1% | -26.6% | 54.2% |
| ROA | -44.3% | -81.1% | -22.7% | -12.6% | -23.1% | 49.6% | -135.0% | -1.2% | -14.4% | -19.2% | 42.6% |
| Net Profit Margin | -172.6% | -133.9% | -42.1% | -23.5% | -42.9% | 131.1% | -171.6% | -1.1% | -35.7% | -30.1% | 61.2% |
| Debt to Equity | 0.24x | 3.70x | 0.83x | 2.34x | 3.24x | 0.06x | 0.07x | 0.06x | 0.04x | 0.04x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biofrontera AG dividends
Biofrontera AG has not paid dividends in the last 9 fiscal years.
Last stock split: 1:21 on May 14, 2024.
Who owns Biofrontera AG
- Insiders 77.00%
- Institutions 0.00%
- Public & others 23.00%
- Shares outstanding 6.08M
- Free float 1.40M
Biofrontera AG company profile
- Company name
- Biofrontera AG
- Ticker
- B8FK.XETRA
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 54
- Fiscal year end
- December
- Address
- Hemmelrather Weg 201, Leverkusen, Germany, 51377
- Phone
- 49 214 87632 0
- Website
- biofrontera.com
About Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Biofrontera AG management
4- Ms. Pilar de la Huerta MartinezCFO & Member of Executive Board · born 1969
- Mr. Alexander RichardsonHead of UK Sales Team
- Dr. Matthias NaumannHead of Sales & Marketing - Europe
- Dr. Montserrat Foguet Ph.D.Managing Director of Biofrontera UK Ltd.